

May 10, 2010
Shionogi & Co., Ltd.

Shionogi Establishes Shionogi Techno Advance Research Co., Ltd.

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President: Isao Teshirogi; hereafter “Shionogi”) today announced that its Board has decided to establish “Shionogi Techno Advance Research Co., Ltd.”, a wholly-owned subsidiary, in September, 2010.

Shionogi has been preparing to enhance the research system for the continuous discovery of new drug candidates to develop and market the original drugs globally. Shionogi aims to achieve the world’s top-level in the research productivity in the Third Medium-Term Business Plan which was initiated from FY2010.

Shionogi will establish the subsidiary for research support and strengthen the support services for experimental research including pharmacological and safety evaluation, which are important in the drug discovery process. The subsidiary will be to accomplish the experimental tasks with high efficiency and enhance Shionogi’s drug discovery research by maintenance and improvement of experimental technology and by the development and securement of human resources.

Shionogi will continuously provide a greater focus on the research and development to create new drugs which satisfy the needs of patients around the world.

New Corporate Overview

Corporate Name:	Shionogi Techno Advance Research Co., Ltd.
Location:	3-1-1, Futaba-cho, Toyonaka, Osaka
Date of Establishment:	September, 2010
Date of Operations Initiation:	October 1, 2010
Initial Capitalization:	9 million yen (wholly-owned by Shionogi)
Representative Person:	Undecided
The main business:	Contract support services for experimental research
Number of Staff:	Approximately 50 (planned)

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:

Corporate Communications Department

Shionogi & Co., Ltd.

Telephone: +81-6-6209-7885

Fax: +81-6-6229-9596